Table 2.
Variable | Hazard Ratio |
||
---|---|---|---|
Model 1 | Model 2 | Model 3 | |
Presence of BMPR2-mutation | 3.38a | 1.153 | 3.529b |
IL-6 | 1.318a | 1.172 | 1.317a |
NT-proBNP | 1.0005a | 1a | 1b |
Prevalent status | 0.9267 | 1.226 | 0.929 |
Tumor necrosis factor-α | 1.126 | 1.099 | 1.126 |
IL-8 | 1.051 | 1.065b | 1.051 |
Mutation:IL-6 | N/A | 1.71b | N/A |
(2.94)b | |||
Mutation:NT-proBNP | N/A | N/A | 1 |
(1) | |||
Akaike information criterion | 173 | 171 | 174 |
Analysis of variance comparison | Basis for comparison | 0.08 | 0.926 |
For models 2 and 3, the estimated hazard ratios in rows 2 to 3 are those associated with per unit increase in IL-6 and NT-proBNP, respectively, for patients who are mutation-negative. By multiplying these values by the hazard ratios for the corresponding interaction terms, we can obtain estimates of the hazard ratios that are associated with IL-6 and NT-proBNP for patients who are BMPR2 mutation-positive (these data are provided in parentheses in the row below). AIC = Akaike information criterion; BMPR2 = bone morphogenetic protein receptor type-2; N/A = not available; NT-proBNP = N-terminal pro-B type natriuretic peptide.
P < .05
P < .1